Prognostic role of clinical and laboratory criteria to identify early ventilator-associated pneumonia in brain injury.

Relationship between feeding tube site and respiratory outcomes. JPEN J Parenter Enteral Nutr (2011) 1.04

Biomarkers: a definite plus in pneumonia. Mediators Inflamm (2009) 0.81

Ventilator-associated pneumonia in critically ill patients with intensive antibiotic usage. Pak J Med Sci (2016) 0.78

PEEP role in ICU and operating room: from pathophysiology to clinical practice. ScientificWorldJournal (2014) 0.78

Ventilator-Associated Pneumonia in Pediatric Traumatic Brain Injury. J Neurotrauma (2015) 0.77

Influence of intraoperative positive end-expiratory pressure level on pulmonary complications in emergency major trauma surgery. Arch Med Sci (2016) 0.75

Decrease in white blood cell counts after thiopentone barbiturate therapy for refractory intracranial hypertension: A common complication. J Neurosci Rural Pract (2013) 0.75

A translational approach to ventilator associated pneumonia. Clin Transl Med (2014) 0.75

Role of C-reactive Protein and Tumor Necrosis Factor-Alpha in Differentiating between Ventilator-Associated Pneumonia and Systemic Inflammatory Response Syndrome without Infectious Etiology. Tanaffos (2016) 0.75

Early-Onset Ventilator-Associated Pneumonia in Patients with Severe Traumatic Brain Injury: Incidence, Risk Factors, and Consequences in Cerebral Oxygenation and Outcome. Neurocrit Care (2017) 0.75

Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91

Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis (2012) 7.97

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64

Protective mechanical ventilation during general anesthesia for open abdominal surgery improves postoperative pulmonary function. Anesthesiology (2013) 5.04

Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ (2010) 3.57

Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis (2011) 3.20

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood (2011) 2.82

A primer of amyloid nomenclature. Amyloid (2007) 2.70

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood (2003) 2.33

A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis (2013) 2.30

Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2012) 2.21

Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med (2003) 2.20

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood (2009) 2.19

Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med (2014) 2.18

Is a strategy based on routine endotracheal cultures the best way to prescribe antibiotics in ventilator-associated pneumonia? Chest (2013) 2.15

Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2005) 2.14

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood (2006) 1.95

Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation (2009) 1.93

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation (2003) 1.93

Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid (2010) 1.91

Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid (2014) 1.91

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol (2008) 1.89

Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest (2006) 1.84

International prognostic scoring system for Waldenstrom macroglobulinemia. Blood (2009) 1.81

Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis (2009) 1.80

Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J (2012) 1.77

Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care Med (2014) 1.77

Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest (2007) 1.77

Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med (2007) 1.75

Proteoglycan fragmentation and respiratory mechanics in mechanically ventilated healthy rats. J Appl Physiol (1985) (2007) 1.74

Reexamining quinolone use in the intensive care unit: use them right or lose the fight against resistant bacteria. Crit Care Med (2005) 1.71

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood (2013) 1.63

Nosocomial pneumonia in the intensive care unit: controversies and dilemmas. J Intensive Care Med (2004) 1.61

Amyloid fibril protein nomenclature -- 2002. Amyloid (2002) 1.59

Hyponatremia in community-acquired pneumonia. Am J Nephrol (2007) 1.59

Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood (2011) 1.58

Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta (2005) 1.58

Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica (2006) 1.53

Low fecal elastase: potentially related to transient small bowel damage resulting from enteric pathogens. J Pediatr Gastroenterol Nutr (2003) 1.52

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood (2006) 1.51

Non-invasive ventilation delivered by conventional interfaces and helmet in the emergency department. Eur J Emerg Med (2003) 1.51

Serum amyloid a and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. Can J Cardiol (2012) 1.51

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood (2007) 1.48

Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU. Crit Care Med (2013) 1.48

Adipokines, hormonal parameters, and cardiovascular risk factors: similarities and differences between patients with erectile dysfunction of arteriogenic and nonarteriogenic origin. J Sex Med (2012) 1.44

Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma (2006) 1.44

Heavy chain disease can be detected by capillary zone electrophoresis. Clin Chem (2005) 1.42

Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol (2005) 1.41

Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem (2009) 1.34

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 1.33

Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clin Cancer Res (2005) 1.32

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood (2004) 1.30

Amyloidosis and Waldenström's macroglobulinemia. Hematology Am Soc Hematol Educ Program (2004) 1.29

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood (2010) 1.27

Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med (2002) 1.27

Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest (2002) 1.27

The controlling roles of Trp60 and Trp95 in beta2-microglobulin function, folding and amyloid aggregation properties. J Mol Biol (2008) 1.24

Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid (2006) 1.22

Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis (2009) 1.21

Protective versus Conventional Ventilation for Surgery: A Systematic Review and Individual Patient Data Meta-analysis. Anesthesiology (2015) 1.19

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol (2013) 1.19

Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid (2002) 1.18

Haematological cancer: Redefining myeloma. Nat Rev Clin Oncol (2012) 1.17

Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol (2007) 1.16

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol (2012) 1.14

Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics (2008) 1.14

New treatment of acute hypoxemic respiratory failure: noninvasive pressure support ventilation delivered by helmet--a pilot controlled trial. Crit Care Med (2002) 1.13

T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis. PLoS One (2012) 1.12

AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly (2012) 1.10

Who should receive antibiotics for exacerbations of chronic bronchitis? A plea for more outcome-based studies. Clin Infect Dis (2004) 1.10

Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum (2009) 1.10

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica (2012) 1.10

Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med (2013) 1.09

Community-acquired pneumonia: an unfinished battle. Med Clin North Am (2011) 1.09

Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I. J Biol Chem (2002) 1.07

Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol (2013) 1.06

Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes--proceedings of the HCAP Summit. Clin Infect Dis (2008) 1.06

The workings of the amyloid diseases. Ann Med (2007) 1.04

Development and preparation of a new serum protein reference material: feasibility studies and processing. Clin Chem Lab Med (2010) 1.03

Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood (2002) 1.03

Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica (2007) 1.01

Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. Stem Cells (2012) 1.00

Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med (2002) 1.00

Diagnosis and treatment of rhinovirus respiratory infections. Chest (2003) 1.00

Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis (2010) 0.99

Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid (2013) 0.98

Management of community-acquired pneumonia: a review and update. Ther Adv Respir Dis (2010) 0.98

Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med (2010) 0.98

Changes in lipid profile in response to three different protocols of whole-body cryostimulation treatments. Cryobiology (2010) 0.98

Tracheostomy must be individualized! Crit Care (2004) 0.98

4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J (2003) 0.97

Noninvasive positive pressure ventilation delivered by helmet vs. standard face mask. Intensive Care Med (2003) 0.97